Hims & Hers Health vs Uncommon Therapeutics

Side-by-side comparison of AI visibility scores, market position, and capabilities

Uncommon Therapeutics leads in AI visibility (27 vs 26)

Hims & Hers Health

EmergingHealthcare

General

Telehealth platform with $872M 2024 revenue; GLP-1 weight loss, hair, and sexual health prescriptions shipped directly to 2M+ subscribers.

AI VisibilityBeta
Overall Score
D26
Category Rank
#422 of 1167
AI Consensus
66%
Trend
stable
Per Platform
ChatGPT
20
Perplexity
18
Gemini
22

About

Hims & Hers Health is a telehealth and wellness platform offering personalized treatment plans and prescription medications for conditions including hair loss, erectile dysfunction, weight management, skincare, and mental health. Founded in 2017 and headquartered in San Francisco, Hims & Hers went public via SPAC merger in January 2021 and has grown into a $1B+ revenue publicly traded health company. The platform connects patients with licensed providers asynchronously and ships prescription treatments directly to homes, eliminating the friction of in-person doctor visits for lifestyle health conditions.

Full profile

Uncommon Therapeutics

EmergingHealthcare

General

Rare disease biotech developing polytherapy approach for Rett Syndrome (1 in 10,000 girls); founder-developed protocol validated through personal patient experience competing with Acadia Pharmaceuticals Daybue in Rett market.

AI VisibilityBeta
Overall Score
D27
Category Rank
#1121 of 1167
AI Consensus
67%
Trend
stable
Per Platform
ChatGPT
28
Perplexity
33
Gemini
36

About

Uncommon Therapeutics is a biotech company founded by Noah Auerhahn — directly inspired by his daughter's diagnosis with Rett Syndrome, a severe genetic neurological disease affecting approximately 1 in 10,000 girls — applying a polytherapy approach (combining multiple therapeutic agents targeting different disease mechanisms simultaneously) to develop treatments for serious neurological and rare diseases. After improving his daughter's quality of life through a personally developed polytherapy protocol, Auerhahn founded Uncommon Therapeutics to translate these insights into pharmaceutical products for the broader Rett Syndrome patient community.

Full profile

AI Visibility Head-to-Head

26
Overall Score
27
#422
Category Rank
#1121
66
AI Consensus
67
stable
Trend
stable
20
ChatGPT
28
18
Perplexity
33
22
Gemini
36
31
Claude
22
29
Grok
33

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.